BD Acquires Atherectomy and Thrombectomy Technologies With Straub Medical

July 20, 2020 – BD (Becton, Dickinson and Company) recently completed the acquisition of Straub Medical AG, a privately-held company that develops and sells medical atherectomy and thrombectomy devices that treat peripheral arterial disease (PAD) and venous disease. 

Currently available in the U.S., Europe and other global regions, the Rotarex S rotational atherectomy system is designed for use in acute, subacute and chronic vessel blockages. Using uniquely designed synchronized mechanisms of action, the Rotarex S system provides clinicians with a single device to negotiate even complex lesions, all with a small equipment footprint that sets up in minutes.

The Aspirex S thrombectomy system is designed to provide continuous aspiration and removal of thrombotic material from blood vessels. The Aspirex S device is currently available in Europe and other global regions. The portfolio also includes additional adjunctive products used in the treatment of PAD and venous disease. 

This acquisition allows BD to immediately deliver advanced technologies in both atherectomy and thrombectomy and further enhances BD’s already strong portfolio of drug-coated, angioplasty and scoring balloons, stents, stent grafts and CTO crossing products for the treatment of PAD and venous disease.

“With our considerable expertise in endovascular technology and strong global infrastructure, BD is the right company to deliver Straub Medical’s atherectomy and thrombectomy products to the market,” said Steve Williamson, worldwide president, Peripheral Intervention at BD. “We are committed to improving the quality of life for the more than 200 million individuals worldwide affected by PAD and are committed to providing more tools for the challenges of managing venous disease. This acquisition allows us to help clinicians treat even more patients.”

Gido Karges, CEO of Straub Medical, added “BD is the ideal strategic match for Straub Medical. With their complementary product portfolio and established global sales channels, BD offers treatment solutions to vascular specialists worldwide. We are excited to join BD in their mission of advancing the world of health.”

For more information: bd.com